You are here

Ketamine Wafer Slated For Study in Phase 3 Trials

Company, FDA held a meeting to discuss trials in bunion, "tummy tuck" patients

iX Biopharma Ltd has successfully concluded an End-of-Phase 2 meeting with the FDA regarding Wafermine, a sublingual ketamine wafer for the treatment of acute moderate to severe pain.

Ketamine is an NMDA antagonist which, unlike opioids, does not cause respiratory depression leading to death if misused. Wafermine has the potential to be used in substitution or as an adjunct to opioids, addressing a large unmet clinical need.

The two parties reached agreement on key aspects of the pivotal phase 3 clinical trial program to support approval of Wafermine for the indication of acute moderate to severe pain. The phase 3 program consists of two randomized, double blind, placebo-controlled studies, one in an orthopedic pain model (bunionectomy) and one in a soft-tissue pain model (abdominoplasty or "tummy tucks"). Both of these postoperative pain models were successfully evaluated in the recent phase 2b clinical study.

Source: iX Biopharma, Dec. 11, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs